265 related articles for article (PubMed ID: 19563648)
1. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
Amini M; Salarifar M; Amirbaigloo A; Masoudkabir F; Esfahani F
Trials; 2009 Jun; 10():45. PubMed ID: 19563648
[TBL] [Abstract][Full Text] [Related]
2. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
Habib M; Hillis A; Hammad A
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
[TBL] [Abstract][Full Text] [Related]
3. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
[TBL] [Abstract][Full Text] [Related]
4. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
5. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
[TBL] [Abstract][Full Text] [Related]
6. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics.
Coyle LC; Rodriguez A; Jeschke RE; Simon-Lee A; Abbott KC; Taylor AJ
Am Heart J; 2006 May; 151(5):1032.e9-12. PubMed ID: 16644332
[TBL] [Abstract][Full Text] [Related]
7. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
[TBL] [Abstract][Full Text] [Related]
9. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
10. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
11. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
[TBL] [Abstract][Full Text] [Related]
13. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial.
Gomes VO; Poli de Figueredo CE; Caramori P; Lasevitch R; Bodanese LC; Araújo A; Röedel AP; Caramori AP; Brito FS; Bezerra HG; Nery P; Brizolara A
Heart; 2005 Jun; 91(6):774-8. PubMed ID: 15894775
[TBL] [Abstract][Full Text] [Related]
14. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
Boccalandro F; Amhad M; Smalling RW; Sdringola S
Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
[TBL] [Abstract][Full Text] [Related]
15. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
[TBL] [Abstract][Full Text] [Related]
16. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
Briguori C; Colombo A; Airoldi F; Violante A; Castelli A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Focaccio A; Ricciardelli B
J Am Coll Cardiol; 2004 Aug; 44(4):762-5. PubMed ID: 15312855
[TBL] [Abstract][Full Text] [Related]
17. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
Goldenberg I; Shechter M; Matetzky S; Jonas M; Adam M; Pres H; Elian D; Agranat O; Schwammenthal E; Guetta V
Eur Heart J; 2004 Feb; 25(3):212-8. PubMed ID: 14972421
[TBL] [Abstract][Full Text] [Related]
18. Could Omega 3 fatty acids reduce the risk of contrast-induced nephropathy in patients undergoing coronary angiography? A randomized controlled trial.
Alrowaie FA; Almatham KI; Alsamadi F; Bashir MS; Munshi HH
Saudi J Kidney Dis Transpl; 2021; 32(2):328-335. PubMed ID: 35017325
[TBL] [Abstract][Full Text] [Related]
19. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
[TBL] [Abstract][Full Text] [Related]
20. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?
Tanaka A; Suzuki Y; Suzuki N; Hirai T; Yasuda N; Miki K; Fujita M; Tanaka T
Intern Med; 2011; 50(7):673-7. PubMed ID: 21467697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
